Related Experiment Videos
Thyroid function in children after cytostatic treatment for acute leukemia
R Nygaard1, K S Bjerve, S Kolmannskog
1Department of Pediatrics, University Hospital, Trondheim, Norway.
Pediatric Hematology and Oncology
|January 1, 1988
Summary
Antileukemic treatment in children, specifically intensive intrathecal methotrexate, did not lead to thyroid dysfunction. This finding suggests that this cytostatic regimen alone is not a cause of this adverse late effect in pediatric cancer survivors.
Area of Science:
- Pediatric Endocrinology
- Hematology-Oncology
- Clinical Toxicology
Background:
- Thyroid dysfunction is a potential adverse late effect following cancer treatment in children.
- Understanding the specific causes of endocrine disorders post-treatment is crucial for long-term survivor care.
Purpose of the Study:
- To investigate thyroid dysfunction as a late effect in children after antileukemic treatment.
- To determine if intrathecal methotrexate, without cranial irradiation, causes thyroid dysfunction.
Main Methods:
- Sixty-one children were evaluated for thyroid dysfunction after completing antileukemic therapy.
- Study focused on patients who received intensive intrathecal methotrexate but not cranial irradiation.
Main Results:
- The cytostatic regimen, consisting of intensive intrathecal methotrexate, did not result in thyroid dysfunction.
- No adverse late effect on thyroid function was observed solely due to this specific treatment protocol.
Conclusions:
- Intensive intrathecal methotrexate treatment alone does not appear to cause thyroid dysfunction in pediatric patients.
- Further research may be needed to fully elucidate all factors contributing to endocrine disorders in cancer survivors.